泌尿外科执业竞争与新诊断前列腺癌的治疗
这项回顾性全国队列研究纳入2014至2018年48,067名新诊断前列腺癌的医保受益人,以Herfindahl-Hirschman指数衡量泌尿外科执业层面市场竞争,按10年非癌死亡风险分层分析治疗使用情况。结果显示,低竞争执业中接受治疗的比例低于高竞争执业(70% vs 67.0%,P < .001),非癌死亡风险最高的男性中,竞争最弱市场执业者接受治疗的可能性低于竞争最强市场执业者(48% vs 60%,P < .001)。结论认为泌尿外科执业间竞争减少与新诊断前列腺癌男性更多接受治疗无关。
要点
- 低竞争执业中前列腺癌治疗率为70%,高竞争执业为67.0%(P < .001)。
- 非癌死亡风险最高男性中,竞争最弱市场治疗率48% vs 竞争最强市场60%(P < .001)。
- 2014至2018年,小型单专科执业泌尿外科医生比例从49%降至41%,多专科执业从38%升至47%。
核心结论
- 泌尿外科执业间竞争减少与新诊断前列腺癌男性更多接受治疗无关,尤其在非癌死亡风险高的男性中。
研究设计与样本
- 回顾性全国队列研究,纳入2014至2018年48,067名新诊断前列腺癌的医保受益人。
- 主要暴露为泌尿外科执业层面市场竞争,市场通过可变半径法按患者流向执业划分,竞争程度每年用Herfindahl-Hirschman指数衡量。
- 主要结局为按10年非癌死亡风险分层的前列腺癌治疗使用(即手术、放疗或冷冻治疗)。
主要发现
- 2014至2018年,在小型单专科组执业的泌尿外科医生总百分比从49%降至41%,多专科执业从38%升至47%。
- 调整人口学和临床特征后,低竞争执业中接受治疗的男性比例低于高竞争执业(70% vs 67.0%,P < .001)。
- 非癌死亡风险最高的男性中,竞争最弱市场执业者接受治疗的可能性低于竞争最强市场执业者(48% vs 60%,P < .001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the effect of urology practice market competition on use of treatment in men with newly diagnosed prostate cancer. METHODS: We performed a retrospective national cohort study of 48,067 Medicare beneficiaries with newly diagnosed prostate cancer between 2014 and 2018. The primary exposure was urology practice-level market competition. Markets were established by the flow of patients to a practice using a variable radius approach. Practice level competition was measured annually using the Herfindahl-Hirschman Index. The primary outcome was use of treatment for prostate cancer (ie, surgery, radiation, or cryotherapy) stratified by 10-year risk of noncancer mortality. RESULTS: Between 2014 and 2018, there was a decrease in the total percent of urologists practicing in small single-specialty groups (49%-41%) with an increase in multispecialty practices (38%-47%). After adjusting for demographic and clinical characteristics, a lower percentage of men underwent treatment in practices with low competition relative to those managed in practices with high competition (70% vs 67.0%, P < .001). Among men with the highest risk of noncancer mortality, those managed in practices in the least competitive markets were less likely to receive treatment relative to men managed by practices in the most competitive markets (48% vs 60%, P-value<.001). CONCLUSION: Reduction in competition between urology practices is not associated with greater use of treatment in men with newly diagnosed prostate cancer, particularly in those with a high risk of noncancer mortality.
引用
- Maganty A, Hollenbeck BK, Kaufman SR, et al. Practice Competition and Treatment of Newly Diagnosed Prostate Cancer. Urology. 2023. PMID: 37146728. doi:10.1016/j.urology.2023.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。